Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 1, Issue 3, pp 161–166 | Cite as

High volume intraperitoneal chemotherapy (“Belly bath”) for ovarian cancer

Pharmacologic basis and early results
  • R. B. Jones
  • C. E. Myers
  • A. M. Guarino
  • R. L. Dedrick
  • Susan M. Hubbard
  • V. T. DeVita
Original Papers Intraperitoneal Chemotherapy

Summary

The currently accepted therapies for ovarian cancer have produced only limited numbers of extended complete remissions in advanced-stage disease. Studies of high-volume intraperitoneal chemotherapy have been initiated to define the toxicology, pharmacokinetics, and the therapeutic effectiveness of this treatment modality. This technique has been virtually ignored until recently, because little success has been achieved with it except in one study (Rutledge, 1966), in which large intraperitoneal fluid volumes were used. The general lack of success probably reflects inadequate attention to physiologic and pharmacologic principles of drug distribution and absorption in a space as large as the peritoneal cavity. Biomedical engineers, pharmacologists, and clinicians at the NCI have cooperated in the development of a rational chemotherapy for ovarian cancer. Following mathematical pharmacokinetic modeling and toxicologic studies in rat, a Phase I clinical trial of intraperitoneal methotrexate administered in large volumes of dialysis fluid was initiated. Results in three patients confirm the practicality of this approach, and further investigation is warranted.

Keywords

Ovarian Cancer Methotrexate Large Volume Treatment Modality Complete Remission 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson, T., Young, R. C.: Recent advances in the staging and treatment of ovarian carcinoma. Med. Clin. N. Amer. 61, 1001 (1977)Google Scholar
  2. Babb, A. L., Johansen, P. J., Strand, M. J., Tenckhoff, H., Scribner, B. H.: Bidirectional permeability of the human peritoneum to middle molecules. Proc. Europ. Dial. Transpl. Ass. 10, 247 (1973)Google Scholar
  3. Bagley, C. M., Young, R. C., Canellos, G. P., DeVita, V. T.: Treatment of ovarian carcinoma: Possibilities for progress. New Engl. J. Med. 287, 856 (1972)Google Scholar
  4. Bagley, C. M., Young, R. C., Schein, P. S., Chabner, B. A., DeVita, V. T.: Ovarian carcinoma metastatic to the diaphragm — frequently undiagnosed at laparotomy. Amer. J. Obstet. Gynec. 116, 397 (1973)Google Scholar
  5. Chabner, B. A., Jacobs, S., Stoller. R. G., Hande, K., Young, R. C.: Methotrexate disposition in humans: Case studies in ovarian cancer and following high-dose infusion. Drug Metab. Rev. (in press, 1978)Google Scholar
  6. Clark, D. G. C., Hilaris, B. S. et al.: Interdisciplinary approach to advanced ovarian cancer. Surg. Clin. N. Amer. 54, 897 (1974)Google Scholar
  7. Clarkson, B., O'Conner, A., Winston, L., Hutchinson, D.: The physiologic dispositions of 5-fluorouracil and 5-fluoro-2′deoxyuridine in man. Clin. Pharmacol. Ther. 5, 581 (1964)Google Scholar
  8. Dedrick, R. L., Zaharko, D. S., Bender, R. A., Bleyer, W. A., Lutz, R. J.: Pharmacokinetic considerations on resistance to anticancer drugs. Cancer Chemother. Rep. 59, 795 (1975)Google Scholar
  9. Dedrick, R. L., Myers, C. E., Bugnay, P. M., DeVita, V. T.: Pharmacokinetic rationale for peritoneal drug administration in treatment of ovarian cancer. Cancer Chemother. Rep. 62, 1 (1978)Google Scholar
  10. Fisher, R. I., Young, R. C.: Advances in the staging and treatment of ovarian cancer. Cancer 39, 967 (1977)Google Scholar
  11. Fuks, F. Y.: External radiotherapy of ovarian cancer: Standard approaches and new frontiers. Semin. Oncol. 2, 253 (1975)Google Scholar
  12. Garrett, E. R., Hurst, G. H., Green, J. R.: Kinetics and mechanisms of drug action on micro-organisms XXIII: Microbial kinetic assay for fluorouracil in biologic fluids and its application to human pharmacokinetics. J. pharm. Sci. 66, 1422 (1977)Google Scholar
  13. Green, T. H.: Hemi-sulfur mustard in the palliation of patients with metastatic ovarian cancer. Obstet. and Gynec. 13, 383 (1959)Google Scholar
  14. Hande, K. R., Balow, J. E., Drake, J. C., Rosenberg, S. A., Chabner, B. A.: Methotrexate and hemodialysis. Ann. intern. Med. 87, 495 (1977)Google Scholar
  15. Hogben, C. A., Tocco, D. J., Brodie, B. G., Schanker, L. S.: On the mechanism of intestinal absorption of drugs. J. Pharmacol. exp. Ther. 275, 125 (1959)Google Scholar
  16. Jaffe, N., Traggis, D.: Toxicity of high-dose methotrexate (NSC-740) and citrovorum factor (NSC-3590) in osteogenic sarcoma. Cancer Chemother. Rep. (Part 3) 6, 31 (1975)Google Scholar
  17. Litterst, C. L., Gram, T. E., Dedrick, R. L., Guarino, A. M.: Distribution and disposition of platinum following IV administration of cis-diamine dichloroplatinum (II) to dogs. Cancer Res. 36, 2340 (1976)Google Scholar
  18. Lukas, G., Brindle, S. D., Greengard, P.: The route of absorption of intraperitoneally administered compounds. J. Pharmacol. exp. Ther. 178, 562 (1971)Google Scholar
  19. Michel, C. C.: Direct observation of sites of permeability for ions and small molecules in mesothelioma and endothelioma. In: Capillary Permeability, p. 623. Copenhagen: Scandinavia University Books 1969Google Scholar
  20. Myers, C. W., Lippman, M. E., Eliot, H. M., Chabner, B. A.: Competitive protein binding assay for methotrexate. Proc. nat. Acad. Sci. (Wash.) 72, 3683 (1975)Google Scholar
  21. Popovich, R. P., Moncrief, J. W., Dechard, J. J., Na, J. S., Sawyer, J. W.: Physiological transport parameters in patients in peritoneum and hemodialysis. In: Proc. 10th Annual Contractors Conference. Artificial Kidney-Chronic Uremia Program, p. 95. Bethesda: National Institute of Arthritis, Metabolism, and Digestive Diseases 1977Google Scholar
  22. Rosenoff, S. H., Young, R. C., Anderson, T., Bagley, C., Chabner, B. A., Schein, P. S., DeVita, V. T.: Peritoneoscopy: a valuable tool for the initial staging and “second look” in ovarian carcinoma. Ann. intern. Med. 83, 37 (1975)Google Scholar
  23. Rosenshaw, N., Blake, D., McIntyre, P. A., Parmley, T., Natarajan, T. K., Dvornicky, J., Nickoloff, E.: The effect of volume on the distribution of substances instilled into the peritoneal cavity. Gynecol. Oncol. (in press, 1978)Google Scholar
  24. Rutledge, F., Burns, B. C.: Chemotherapy for advanced ovarian cancer. Comment by C. P. Hodgkinson. Amer. J. Obstet. Gynec. 96, 771 (1966)Google Scholar
  25. Silberberg, E., Holleb, A. I.: Cancer statistics, 1971. Cancer 21, 13 (1971)Google Scholar
  26. Sullivan, R. D., Miller, E., Furck, W. F.: Re-evaluation of methotrexate as an anticancer drug. Surg. Gynec. Obstet. 125, 819 (1967)Google Scholar
  27. Tenckhoff, H., Schachter, H.: A bacteriologically safe peritoneal access device. Trans. Amer. Soc. artif. intern. Org. 14, 181 (1968)Google Scholar
  28. Torres, I. J., Litterst, C. L., Guarino, A. M.: Transport of model compounds across the peritoneal membrane in the rat. Pharmacology (in press, 1978)Google Scholar
  29. Young, R. C., Anderson, T.: Ovarian and testicular malignancies: Progress in management of tumors derived from the genital ridge. In: Recent Advances in Cancer Treatment, p. 325. New York: Raven Press 1977Google Scholar
  30. Young, R. C., DeVita, V. T., Chabner, B. A.: A prospective trial of melphalan (PAM) and combination chemotherapy in advanced ovarian cancer. Proc. Amer. Soc. clin. Oncol. 12, 279 (1976)Google Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • R. B. Jones
    • 1
  • C. E. Myers
    • 1
  • A. M. Guarino
    • 1
  • R. L. Dedrick
    • 1
  • Susan M. Hubbard
    • 1
  • V. T. DeVita
    • 1
  1. 1.National Cancer Institute, National Institutes of Health, Public Health ServiceU.S. Department of Health Education, and WelfareBethesdaUSA

Personalised recommendations